<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974777</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAL-PCI v.2</org_study_id>
    <nct_id>NCT02974777</nct_id>
  </id_info>
  <brief_title>The IDEAL-PCI Extended Registry</brief_title>
  <acronym>IDEAL-PCI ext</acronym>
  <official_title>Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Franz Josef Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Franz Josef Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a routine
      individualized antiplatelet therapy after coronary stent implantation by evaluating
      &quot;on-treatment&quot; platelet reactivity with Multiple Electrode Aggregometry (MEA, MultiplateÂ®
      Analyzer).

      IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on
      bleeding events and net clinical benefit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determination of platelet reactivity in patients with percutaneous coronary Intervention as
      described in the IDEAL-PCI registry.

      In the IDEAL-PCI Extended Registry an additional deescalation arm with reduction of the
      standard dual antiplatelet therapy (DAPT) dosis in case of low platelet reactivity to P2Y12
      Inhibition or Aspirin with or without bleeding is implemented.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>stent thrombosis by any Academic Research Consortium (ARC) definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>bleeding type 1-3 and 5 by Bleeding Academic Research Consortium (BARC) definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular Events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>death, cardiovascular death, myocardial infarction, stroke, ischemia driven revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Arterioscleroses</condition>
  <condition>Platelet Dysfunction Due to Drugs</condition>
  <arm_group>
    <arm_group_label>Bleeding prevention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemia prevention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPT reduction</intervention_name>
    <description>Reduction of standard dose DAPT due to low platelet reactivity</description>
    <arm_group_label>Bleeding prevention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPT on-target</intervention_name>
    <description>Standard DAPT within the therapeutic window of platelet reactivity</description>
    <arm_group_label>Bleeding prevention group</arm_group_label>
    <arm_group_label>Ischemia prevention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPT intensification</intervention_name>
    <description>Intensification of standard dose DAPT due to high platelet reactivity</description>
    <arm_group_label>Ischemia prevention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all consecutive PCI patients

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Christ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Franz Josef Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guenter Christ, MD</last_name>
    <phone>+43-1-60191</phone>
    <phone_ext>72522</phone_ext>
    <email>guenter.christ@wienkav.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guenter Christ, MD</last_name>
      <phone>+43160191</phone>
      <phone_ext>2508</phone_ext>
      <email>guenter.christ@wienkav.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT01515345</url>
    <description>IDEAL-PCI Registry</description>
  </link>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 25, 2016</lastchanged_date>
  <firstreceived_date>November 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaiser Franz Josef Hospital</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Guenter Christ</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
